FDA — authorised 2 September 2009
- Application: NDA022037
- Marketing authorisation holder: TAKEDA PHARMS USA
- Status: supplemented
FDA authorised Intuniv on 2 September 2009 · 1,832 US adverse-event reports
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Yes. FDA authorised it on 2 September 2009; FDA has authorised it.
TAKEDA PHARMS USA holds the US marketing authorisation.